About
ALKemist Bio
A cross-continental team of scientists, clinicians, and innovators advancing immuno-therapies against ALK-driven cancers.
ALKemist Bio was founded on the scientific vision and research of Professor Roberto Chiarle, whose work has been instrumental in uncovering the role of ALK in cancer biology.
At ALKemist Bio, we develop therapies that target the ALK oncogene—an established cancer driver often overlooked by existing immunotherapies.
Our therapies leverage autologous T cells that are genetically engineered ex vivo to express synthetic receptors (CAR and TCR) with high affinity for the ALK protein, whether displayed on the cell surface as a transmembrane protein or presented as peptide-MHC complexes. This strategy enables broad applicability across a range of ALK-positive cancers—including lymphoma, neuroblastoma, and NSCLC—while ensuring a rigorous safety profile.
Expanded under controlled conditions, these ALK-targeting T cells are reinfused into patients with the capacity to recognize and eliminate tumor cells and provide sustained immune surveillance, even in cases where resistance to standard treatments has emerged.
The team
